“Bimekizumab Efficacy and Safety Over 48 Weeks in US and Canadian Patients with Psoriasis who had a Treatment Interruption After 3 Years of Treatment: Results from BE RADIANT”, J of Skin, vol. 8, no. 6, p. s431, Nov. 2024, doi: 10.25251/skin.8.supp.431.